Welireg, Padcev, and a surprise fillip for Flare.
ApexOnco Front Page
Recent articles
Two new pivotal Chinese first-line trials have started in lung cancer.
A pipeline cull sees the US pharma joining AbbVie's exit, in the wake of Novartis’s big bet.
Abstract titles reveal some of ASCO’s key datasets.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
The Swiss company is still interested in this antigen, after discontinuing two earlier clinical projects.
Amid doubts about early data with FG-3246, the group is scathing about its rivals.